脑肿瘤患者正电子发射断层扫描成像的现状和新兴领域。

Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener St. 62, 50937 Cologne, Germany.

Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Leo-Brandt-St., 52425 Juelich, Germany.

Molecules. 2020 Mar 24;25(6):1471. doi: 10.3390/molecules25061471.

The number of positron-emission tomography (PET) tracers used to evaluate patients with brain tumors has increased substantially over the last years. For the management of patients with brain tumors, the most important indications are the delineation of tumor extent (e.g., for planning of resection or radiotherapy), the assessment of treatment response to systemic treatment options such as alkylating chemotherapy, and the differentiation of treatment-related changes (e.g., pseudoprogression or radiation necrosis) from tumor progression. Furthermore, newer PET imaging approaches aim to address the need for noninvasive assessment of tumoral immune cell infiltration and response to immunotherapies (e.g., T-cell imaging). This review summarizes the clinical value of the landscape of tracers that have been used in recent years for the above-mentioned indications and also provides an overview of promising newer tracers for this group of patients.

近年来，用于评估脑肿瘤患者的正电子发射断层扫描（PET）示踪剂的数量大幅增加。对于脑肿瘤患者的管理，最重要的适应症是肿瘤范围的描绘（例如，用于规划切除或放疗）、评估系统治疗方案（如烷化化疗）的治疗反应，以及区分治疗相关变化（例如，假性进展或放射性坏死）与肿瘤进展。此外，更新的 PET 成像方法旨在满足对肿瘤免疫细胞浸润和免疫治疗反应的非侵入性评估的需求（例如，T 细胞成像）。这篇综述总结了近年来用于上述适应症的示踪剂的临床价值，并概述了这组患者中具有前景的新型示踪剂。